Publications by authors named "D Balducci"
Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist approved for the treatment of Crohn's disease (CD). Only limited real-life data on the long-term outcomes of CD patients treated with UST are available. This study assessed UST's long-term effectiveness and safety in a large population-based cohort of moderate to severe CD patients.
View Article and Find Full Text PDFArticle Synopsis
- EUS-guided hepaticojejunostomy (EUS-HJS) is a biliary drainage technique for patients with altered anatomy, particularly those who have had total gastrectomy, but data on its effectiveness were previously lacking.
- A retrospective study involving 21 patients found that EUS-HJS achieved 100% technical success and 80% clinical success, helping to alleviate symptoms like jaundice and cholangitis.
- Although the procedure had a 33% adverse event rate, many patients (39%) could resume cancer treatment, and the median survival time after the procedure was 6 months.
Hepatocellular carcinoma (HCC) is undergoing a transformative shift, with metabolic-associated fatty liver disease (MAFLD) emerging as a dominant etiology. Diagnostic criteria for MAFLD involve hepatic steatosis and metabolic dysregulation. Globally, MAFLD prevalence stands at 38.
View Article and Find Full Text PDFEndoluminal biliary radiofrequency ablation (RFA) has been proposed as a palliative treatment for patients with malignant biliary obstruction (MBO) in order to improve stent patency and survival. However, the existing data on patients with inoperable extrahepatic cholangiocarcinoma (eCCA) are conflicting. We performed a meta-analysis of randomized trials comparing RFA plus stenting versus stenting alone in patients with inoperable eCCA.
View Article and Find Full Text PDF